Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
Radiopharm Theranostics announced positive Phase 2b trial results for RAD101, an imaging agent for diagnosing brain metastases, showing 93% concordance with MRI. The company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026, targeting a $600+ million market with …